What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Cancer research, Wilms' tumor, Leukemia, Immunology and Immunotherapy are his primary areas of study.
The concepts of his Cancer research study are interwoven with issues in Carcinogenesis, Tumor suppressor gene, Cancer immunotherapy, K562 cells and Cytotoxic T cell.
His Wilms' tumor research includes elements of Vaccination, Gene and Minimal residual disease.
His Leukemia study incorporates themes from Myeloid, Myeloid leukemia and Bone marrow.
His Immunology study often links to related topics such as Cancer.
His Immunotherapy research integrates issues from Epitope and Lung cancer.
His most cited work include:
- WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. (538 citations)
- Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression (496 citations)
- Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human Leukemia (339 citations)
What are the main themes of his work throughout his whole career to date?
Haruo Sugiyama mainly investigates Cancer research, Immunology, Internal medicine, Wilms' tumor and Leukemia.
Haruo Sugiyama has researched Cancer research in several fields, including Cancer, Cancer immunotherapy, Immunotherapy, Gene and Cytotoxic T cell.
His Immunotherapy research incorporates themes from Adjuvant and Peptide.
The Internal medicine study combines topics in areas such as Gastroenterology, Oncology and Glioma.
His Wilms' tumor research includes themes of Carcinogenesis and Tumor suppressor gene.
His Leukemia research incorporates elements of Myeloid, Hematopoietic stem cell transplantation, Myeloid leukemia and Bone marrow.
He most often published in these fields:
- Cancer research (40.05%)
- Immunology (28.61%)
- Internal medicine (23.98%)
What were the highlights of his more recent work (between 2013-2021)?
- Cancer research (40.05%)
- Immunology (28.61%)
- Internal medicine (23.98%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Cancer research, Immunology, Internal medicine, Immunotherapy and Wilms' tumor.
As part of the same scientific family, Haruo Sugiyama usually focuses on Cancer research, concentrating on MHC class I and intersecting with MHC class II and Chemoimmunotherapy.
As a part of the same scientific study, Haruo Sugiyama usually deals with the Immunology, concentrating on Cytotoxic T cell and frequently concerns with Antigen, CD8 and Molecular biology.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Oncology and Glioma.
His Wilms' tumor study combines topics from a wide range of disciplines, such as Tolerability, Chemoradiotherapy and Myelodysplastic syndromes.
Haruo Sugiyama focuses mostly in the field of Leukemia, narrowing it down to topics relating to Hematopoietic stem cell transplantation and, in certain cases, Minimal residual disease.
Between 2013 and 2021, his most popular works were:
- Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia (86 citations)
- Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer (82 citations)
- Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer (58 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His primary scientific interests are in Immunology, Cancer research, Internal medicine, Oncology and Wilms' tumor.
Minimal residual disease is closely connected to Hematopoietic stem cell transplantation in his research, which is encompassed under the umbrella topic of Immunology.
Haruo Sugiyama interconnects Cancer, Cell growth, Apoptosis, Cytotoxic T cell and Bone marrow in the investigation of issues within Cancer research.
Within one scientific family, Haruo Sugiyama focuses on topics pertaining to Vaccination under Internal medicine, and may sometimes address concerns connected to Glioma and Dendritic cell.
The study incorporates disciplines such as Clinical trial, Pancreatic cancer, Cancer vaccine and Tolerability, Adverse effect in addition to Wilms' tumor.
His Leukemia study integrates concerns from other disciplines, such as Myeloid and microRNA.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
